Why The EU’s New Clinical Trials System Is Taking So Long
Technical complexities mean that the finalization of the EU’s much vaunted clinical trial portal and database system has been pushed back yet again, this time to early or mid-2020.
You may also be interested in...
Despite Brexit, the UK is still seen as an attractive place to do clinical research, according to the Medicines and Healthcare products Regulatory Agency. However, the agency's involvement in the EU Voluntary Harmonization Procedure has taken a hit.
Amid a recent stock price rigging scandal involving a local bioventure, and the global push to improve the transparency of clinical trials, Korean financial authorities are pushing for improved public disclose by pharma/biotech companies of key information on clinical development, such as trial failures or suspensions, to better inform investors.
The EMA is to further refocus on its core activities to help it deal with “higher than expected” staff losses due to its relocation to Amsterdam.